Overview

the Accuracy and Safety of Coronary Artery Contrast-enhanced Magnetic Resonance Imaging With Polysaccharide Superparamagnetic Iron Oxide Nanoparticle

Status:
Not yet recruiting

Trial end date:
2022-07-01

Target enrollment:

Participant gender:

Summary

This is a single-center, prospective, controlled and diagnostic clinical trial which will enroll 30 patients scheduled for coronary angiography in China.Patients will receive contrast-enhanced cardiac magnetic resonance with polysaccharide superparamagnetic iron oxide nanoparticle before percutaneous coronary angiography.In order to evaluate the safety of polysaccharide superparamagnetic iron oxide nanoparticle, patients will detect iron levels in peripheral and tissue before and after the examination.The main indicators of the study are the degree of coronary artery stenosis and the stability of coronary atherosclerotic plaque assessed by contrast-enhanced cardiac magnetic resonance with polysaccharide superparamagnetic iron oxide nanoparticle.

Phase:

Phase 1

Details

Lead Sponsor:

The First Affiliated Hospital with Nanjing Medical University

Collaborators:

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
School of Biomedical Engineering & Informatics, Nanjing Medical University
School of Bioscience & Medical Engineering, Southeast University